Moderna (LIM:MRNA) Inventories, Finished Goods : $24 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Moderna Inventories, Finished Goods?

Moderna's quarterly finished goods increased from Jun. 2023 ($12 Mil) to Sep. 2023 ($277 Mil) but then declined from Sep. 2023 ($277 Mil) to Dec. 2023 ($24 Mil).

Moderna's annual finished goods declined from Dec. 2021 ($233 Mil) to Dec. 2022 ($169 Mil) and declined from Dec. 2022 ($169 Mil) to Dec. 2023 ($24 Mil).

Moderna Inventories, Finished Goods Historical Data

The historical data trend for Moderna's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Inventories, Finished Goods Chart

Moderna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

Get a 7-Day Free Trial

1.00

233.00

169.00

24.00

Moderna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventories, Finished Goods	Get a 7-Day Free Trial															169.00	64.00	12.00	277.00	24.00

Moderna Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Moderna (LIM:MRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (LIM:MRNA) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

MRNA:USA MRNA:Mexico 0QFd:UK 0A45:UK 0QF:Germany M1RN34:Brazil MRNA:Austria

Address

200 Technology Square, Cambridge, MA, USA, 02139

Website

https://www.modernatx.com

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.